Related references
Note: Only part of the references are listed.Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer
Chieh-Chien Lee et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Modeling NSCLC Progression: Recent Advances and Opportunities Available
Ahmed Abbas Suleiman et al.
AAPS JOURNAL (2013)
Preclinical Pharmacokinetic/Pharmacodynamic Models to Predict Schedule-Dependent Interaction Between Erlotinib and Gemcitabine
Mengyao Li et al.
PHARMACEUTICAL RESEARCH (2013)
Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial
Giorgio V. Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Sunitinib Plus Erlotinib for the Treatment of Advanced/Metastatic Non-Small-Cell Lung Cancer A Lead-In Study
George R. Blumenschein et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies
Virginie Poindessous et al.
CLINICAL CANCER RESEARCH (2011)
Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Inhibition and Biomarker Modulation by the Novel Phosphatidylinositol 3-Kinase Inhibitor GDC-0941
Laurent Salphati et al.
DRUG METABOLISM AND DISPOSITION (2010)
Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species
Joshua Oe Haznedar et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Clinical pharmacokinetics of tyrosine kinase inhibitors
Nielka P. van Erp et al.
CANCER TREATMENT REVIEWS (2009)
Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
George N. Naumov et al.
CLINICAL CANCER RESEARCH (2009)
Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development
Y. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Modeling of tumor growth and anticancer effects of combination therapy
Gilbert Koch et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2009)
A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine plus carboplatin in non-small cell lung cancer patients
Lai-San Tham et al.
CLINICAL CANCER RESEARCH (2008)
Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications
Giampaolo Tortora et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies
Radojka M. Savic et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2007)
Predicting the active doses in humans from animal studies: A novel approach in oncology
M. Rocchetti et al.
EUROPEAN JOURNAL OF CANCER (2007)
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
S Faivre et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Pharmacokinetic/pharmacodynamic modelling in oncological drug development
MO Karlsson et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2005)
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents
M Simeoni et al.
CANCER RESEARCH (2004)
Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer
R Pérez-Soler et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Rhebbing up mTOR - New insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis
DJ Kwiatkowski
CANCER BIOLOGY & THERAPY (2003)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Share Paper
